Studies on HK-II, PFK-1/PFKFB3 and PKM2 in the pathogenesis of RA have facilitated the development of new DMARDs targeting rate-limiting enzymes of the glycolytic pathway to implement new anti-rheumatic therapies. Here, PKM is linked to rheumatoid arthritis.